4,901 trials
Bacterial Infections · Obesity
Primary: Pharmacokinetics (PK) - Clearance (Cl) in Participants Who Received Multiple Doses of Intravenous (IV) Clindamycin. — 4.2; 5.7; 12.5; 10.7 L/h
Solid Tumour
Primary: Number of Patients Experiencing Dose Limiting Toxicity (DLT) — 0; 0; 0; 1 Number of patients with DLT
Healthy Volunteer
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (AUC[0-inf]) of Alectinib — 1920; 1840; 1850; 1630 ng*hour/mL
Healthy Volunteer
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (AUC[0-inf]) of Alectinib — 3990; 1020 ng*hour/mL
Hereditary Tyrosinemia, Type I
Primary: Maximum Observed Plasma Concentration (Cmax) — 1277.77; 1272.34; 1339.79 ng/mL
Oncology
Primary: Absolute Oral Bioavailability — 69.75 Percentage
Healthy Volunteer
Primary: Maximum Observed Plasma Concentration (Cmax) of Alectinib: Cohort A — 27.6; 35.0 nanograms per milliliter (ng/mL)
End Stage Renal Disease
Primary: Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Single 5mg Oral Dose of Apixaban — 125.6; 98.9; 113.6 ng/mL
Pachyonychia Congenita
Primary: Evaluation of Systemic Absorption Through Measurement of Serum Sirolimus Trough Levels — 15; 15; 15; 14 participants
Healthy Volunteer
Primary: Maximum Observed Plasma Concentration (Cmax) of Alectinib: Group 1 — 103; 270 nanograms per milliliter (ng/mL)
B-cell Small Lymphocytic Lymphoma Recurrent
Primary: Response — 3; 2; 1; 4 participants
Friedreich's Ataxia
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) — 3; 0; 4; 5 participants
Melanoma
Primary: Number of Participants Experiencing Adverse Events (AEs) — 34; 8 Participants
Atopic Dermatitis
Primary: Cmax of OPA-15406 in a Single Administration Period — 0.508; 0.838; 1.61 ng/mL
Hearing Impairment
Primary: Maximum Effective Sound Pressure Level (MEPO) — 95 decibels (dB) Sound Pressure Level (SPL)